Nasdaq auph.
Nov 24, 2023 · Aurinia Pharmaceuticals Inc (NASDAQ:AUPH)’s traded shares stood at 0.69 million during the latest session, with the company’s beta value hitting 1.28. At the last check today, the stock’s price was $9.28, to imply an increase of 2.66% or $0.24 in intraday trading.
Jun 16, 2023 · Aurinia Pharmaceuticals Inc. (NASDAQ:AUPH) is a good speculative biotech play to look into. That's because it already has received FDA approval of LUPKYNIS™ as an oral treatment for adult ... NEW YORK, May 29, 2022 (GLOBE NEWSWIRE) -- Bragar Eagel & Squire, P.C., a nationally recognized shareholder rights law firm, reminds investors that...NEW YORK, May 18, 2022 (GLOBE NEWSWIRE) -- Bragar Eagel & Squire, P.C., a nationally recognized shareholder rights law firm, reminds investors that...A. Aurinia Pharmaceuticals ( AUPH) does not have any upcoming earnings reports scheduled yet. The last reported earnings were for reported on November 2, 2023 for Q3 and the Actual Revenue was $54 ...Discover historical prices for AUPH stock on Yahoo Finance. View daily, weekly or monthly format back to when Aurinia Pharmaceuticals Inc. stock was issued.
Aurinia Pharmaceuticals Inc Ordinary Shares (AUPH) Real-time Stock Quotes - Nasdaq offers real-time quotes & market activity data for US and global markets.VICTORIA, British Columbia--(BUSINESS WIRE)--Aurinia Pharmaceuticals Inc. (NASDAQ: AUPH) (Aurinia or the Company) today announced that it will release financial and operational results for third ...Find the latest historical data for Aurinia Pharmaceuticals Inc Ordinary Shares (AUPH) at Nasdaq.com.
Aurinia Pharmaceuticals (AUPH) closed the last trading session at $9.80, gaining 0.9% over the past four weeks, but there could be plenty of upside left in the stock if short-term price targets ...
(NASDAQ: AUPH) Aurinia Pharmaceuticals currently has 143,608,164 outstanding shares. With Aurinia Pharmaceuticals stock trading at $8.23 per share, the total value of Aurinia Pharmaceuticals stock (market capitalization) is $1.18B .December 4, 2023. Business. B. Riley Financial Inc (NASDAQ:RILY) has a beta value of 1.57 and has seen 0.91 million shares traded in the recent trading session. The company, currently valued at $723.52M, closed the recent trade at $23.66 per share which meant it gained $3.51 on the day or 17.42% during that session.Last month, AUPH's second largest shareholder, MKT Capital, which holds 4.2% of the stock, wrote a scathing letter to shareholders, calling to withdraw support for CEO Peter Greenleaf, board ...During the last session, Aurinia Pharmaceuticals Inc (NASDAQ:AUPH)’s traded shares were 2.07 million, with the beta value of the company hitting 1.26. At the end of the trading day, the stock’s price was $8.64, reflecting an intraday gain of 0.47% or $0.04. The 52-week high for the AUPH share is ...Rhumbline Advisers raised its position in shares of Aurinia Pharmaceuticals Inc. (NASDAQ:AUPH – Free Report) (TSE:AUP) by 3.2% in the 2nd quarter, according to the company in its most recent ...
SAN DIEGO, April 20, 2022 (GLOBE NEWSWIRE) -- The law firm of Robbins Geller Rudman & Dowd LLP announces that purchasers of Aurinia Pharmaceuticals Inc. (NASDAQ: AUPH) securities between May 7 ...
Anyone who held Aurinia Pharmaceuticals Inc. (NASDAQ:AUPH) over the last year knows what a loser feels like. The share price has slid 66% in that time. On the bright side, the stock is actually up 50%
Financials. AUPH has a market cap of $1.3bn and a cash balance of $389mn. Research and development expenses were USD 9.9 million for 4Q. Selling, general and administrative expenses, inclusive of ...9th Floor. Toronto, ON M5J 2Y1. Canada. T: +1-514-982-7555. [email protected]. https://www.computershare.com. Aurinia Pharmaceuticals is a fully integrated biopharmaceutical company focused on delivering therapies to treat targeted patient populations that are impacted by serious diseases with a high unmet …Nov 27, 2023 · Aurinia Pharmaceuticals Inc., a commercial-stage biopharmaceutical company, focuses on developing and commercializing therapies to treat various diseases with unmet medical need in the United States. The company also offers LUPKYNIS for the treatment of adult patients with active lupus nephritis. It has a collaboration and license agreement ... Nasdaq provides company’s , which are financial statements and reports filed electronically with the U.S. Securities and Exchange Commission (SEC) by Quotemedia. The SEC requires all publicly ... Nov 24, 2021 · Every investor in Aurinia Pharmaceuticals Inc. (NASDAQ:AUPH) should be aware of the most powerful shareholder groups. Institutions will often hold stock in bigger companies, and we expect to see ... Aurinia Pharmaceuticals ( NASDAQ: AUPH) traded ~5% higher pre-market Thursday after the Canadian biotech increased its full-year guidance and posted better-than-expected financials for Q2 2023 ...
See historical performance and comparison. View Valuation. Research Aurinia Pharmaceuticals' (Nasdaq:AUPH) stock price, latest news & stock analysis. Find …We feel now is a pretty good time to analyse Aurinia Pharmaceuticals Inc.'s (NASDAQ:AUPH) business as it appears the company may be on the cusp of a considerable accomplishment. Aurinia ...With the business potentially at an important milestone, we thought we'd take a closer look at Aurinia Pharmaceuticals Inc.'s (NASDAQ:AUPH) future prospects. Aurinia Pharmaceuticals Inc., a ...Nov 17, 2023 · msn.com - August 8 at 2:56 PM. Jump Financial LLC Takes $366,000 Position in Aurinia Pharmaceuticals Inc. (NASDAQ:AUPH) marketbeat.com - August 8 at 5:21 AM. Aurinia Pharmaceuticals Inc. (NASDAQ:AUPH) to Post Q1 2024 Earnings of ($0.14) Per Share, Leerink Partnrs Forecasts. marketbeat.com - August 7 at 7:47 AM. Zacks earnings numbers are reported on a BNRI (Before Non Recurring Items) basis and include stock option expenses where possible. Nasdaq provides visual representation of analyst expected ...This page of Aurinia Pharmaceuticals (AUPH) displays a brief signal update and a market outlook, as well as a candlestick chart showing the last detected ...Find the latest dividend history for Aurinia Pharmaceuticals Inc Ordinary Shares (AUPH) at Nasdaq.com.
That’s sort of the situation with Aurinia Pharmaceuticals (NASDAQ:AUPH). A ton hinges on a late-stage trial reporting at the end of the year. However, it’s a gamble that may be worth looking at.Nov 29, 2023 · 2 analysts have issued twelve-month price targets for Aurinia Pharmaceuticals' stock. Their AUPH share price targets range from $13.00 to $15.00. On average, they expect the company's stock price to reach $14.00 in the next year. This suggests a possible upside of 62.8% from the stock's current price. View analysts price targets for AUPH or ...
Aurinia Pharmaceuticals Inc Ordinary Shares (AUPH) Option Chain | Nasdaq. Call and put options are quoted in a table called a chain sheet. The chain sheet shows the price, volume and open interest ...Price. 9.06. +4.86%. Webull offers AUPH Ent Holdg (AUPH) historical stock prices, in-depth market analysis, NASDAQ: AUPH real-time stock quote data, in-depth charts, free AUPH options chain data, and a fully built financial calendar to help you invest smart. Buy AUPH stock at Webull. NASDAQ, Inc. short interest is available by issuer for the past 12 months and updated twice a month. Short interest data is reported on mid-month and end-of-month settlement dates. It is then ... Aurinia Pharmaceuticals Inc Ordinary Shares (AUPH) Real-time Stock Quotes - Nasdaq offers real-time quotes & market activity data for US and global markets.Aurinia Pharmaceuticals (AUPH) closed the last trading session at $9.80, gaining 0.9% over the past four weeks, but there could be plenty of upside left in the stock if short-term price targets ...And Aurinia Pharmaceuticals Inc (Symbol: AUPH) saw options trading volume of 18,237 contracts, representing approximately 1.8 million underlying shares or approximately 88.5% of AUPH's average ...A. Aurinia Pharmaceuticals ( AUPH) does not have any upcoming earnings reports scheduled yet. The last reported earnings were for reported on November 2, 2023 for Q3 and the Actual Revenue was $54 ...Nov 20, 2023 · Nov. 20, 2023, 12:38 PM. Aurinia Pharmaceuticals Inc (NASDAQ:AUPH) shares are trading higher, adding to gains of more than 17% over the last week. The stock has been trending higher since the ... See the latest Aurinia Pharmaceuticals Inc stock price (AUPH:XNAS), related news, valuation, dividends and more to help you make your investing decisions.Aurinia Pharmaceuticals (AUPH) closed the last trading session at $9.80, gaining 0.9% over the past four weeks, but there could be plenty of upside left in the stock if short-term price targets ...
Aurinia Pharmaceuticals Inc.'s (NASDAQ:AUPH) value has fallen 11% in the last week, but insiders who sold US$32m worth of stock over the last year have had less success. Insiders would probably ...
Big Biotech Stocks to Buy Under $10 #4: Aurinia Pharmaceuticals (AUPH) Source: Aurinia. Share Price: $5.46. Lupus remains one of the least understood auto-immune diseases. With lupus, the body’s ...
Aurinia Pharmaceuticals Inc. (NASDAQ:AUPH) BELLUS Health Inc. (NASDAQ:BLU) (announced positive findings from the Phase 2b study of BLU-5937 in patients with refractory chronic cough) Bio-Techne ...The FDA is scheduled to rule on Aurinia Pharmaceuticals Inc's (NASDAQ:AUPH) voclosporin as a treatment option for lupus nephritis. SHARE THIS POST. FACEBOOK. TWITTER. EMAIL. COPY LINK.Aurinia Pharmaceuticals (NASDAQ:AUPH) is a biopharmaceutical firm delivering therapies for autoimmune, kidney, and rare diseases with unmet medical needs. In 2021, it introduced Lupkynis ...About Latest Pre-Market Trades. Nasdaq provides market information before market opens daily from 4:15 A.M. ET to 7:30 A.M. ET on the following day.Aurinia Pharmaceuticals Inc (NASDAQ:AUPH) initiated an exploration of strategic alternatives, including a potential sale, merger, or other strategic transaction.. Aurinia has retained JP Morgan as ...Canadian biotech Aurinia Pharmaceuticals ( NASDAQ: AUPH) jumped ~11% pre-market Wednesday after announcing that the company is on track to receive two new patents in the U.S. and EU covering its ...Aug 18, 2021 · Aurinia AUPH announced that it has acquired two new pipeline candidates, which will target rare autoimmune and kidney-related diseases. Both the candidates, renamed as AUR200 and AUR300 following ... To wit, the Aurinia Pharmaceuticals Inc. (NASDAQ:AUPH) share price is 78% higher than it was a year ago, much better than the market return of around 12% (not including dividends) in the same ...
Aurinia Pharmaceuticals Inc (NASDAQ:AUPH) institutional ownership structure shows current positions in the company by institutions and funds, as well as latest ...Canadian biotech Aurinia Pharmaceuticals ( NASDAQ: AUPH) jumped ~11% pre-market Wednesday after announcing that the company is on track to receive two new patents in the U.S. and EU covering its ...Jan 5, 2023 · Aurinia Pharmaceuticals (NASDAQ:AUPH) recently announced they have reached a settlement with Sun Pharmaceuticals (OTCPK:SMPQY) to dismiss their claims and counterclaims against each other. Aurinia Pharmaceuticals ( NASDAQ: AUPH) named Dr. Robert Foster as a new board member Thursday as part of an agreement with its major shareholder and investment management firm, MKT Capital Ltd ...Instagram:https://instagram. best broker for shortingmaybach electricmetaverse stockgoldman sachs sandp 500 forecast 2023 View the latest Aurinia Pharmaceuticals Inc. (AUPH) stock price, news, historical charts, analyst ratings and financial information from WSJ.Canadian biotech Aurinia Pharmaceuticals ( NASDAQ: AUPH) jumped ~11% pre-market Wednesday after announcing that the company is on track to receive two new patents in the U.S. and EU covering its ... g23ayousolar stock That’s sort of the situation with Aurinia Pharmaceuticals (NASDAQ:AUPH). A ton hinges on a late-stage trial reporting at the end of the year. However, it’s a gamble that may be worth looking at.Fintel reports that on September 22, 2023, HC Wainwright & Co. reiterated coverage of Aurinia Pharmaceuticals (NASDAQ:AUPH) with a Buy recommendation. Analyst Price Forecast Suggests 72.67% Upside ... amazon stock rating Shares of Aurinia Pharmaceuticals Inc. AUPH gained 13.2% on Dec 2, following fresh rumors of a potential buyout. Reportedly, Swiss pharma giant Novartis NVS is looking out for small bolt-on ...Aurinia Pharmaceuticals ( NASDAQ: AUPH) traded ~5% higher pre-market Thursday after the Canadian biotech increased its full-year guidance and posted better-than-expected financials for Q2 2023 ...Feb 28, 2022 · What happened. Shares of the autoimmune disease specialist Aurinia Pharmaceuticals (NASDAQ: AUPH) are poised for a tough session today. Ahead of the opening bell, the drugmaker's share price ...